Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report

Pediatr Radiol. 2014 Feb;44(2):173-80. doi: 10.1007/s00247-013-2795-x. Epub 2013 Sep 21.

Abstract

Background: Nephrogenic systemic fibrosis is a fibrosing disorder associated with exposure to gadolinium-based contrast agents in people with severely compromised renal function.

Objective: The purpose of this study was to determine the reported number of cases of nephrogenic systemic fibrosis in children using three distinct publicly available data sources.

Materials and methods: We conducted systematic searches of the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), the International Center for Nephrogenic Systemic Fibrosis Research (ICNSFR) registry and published literature from January 1997 through September 2012. We contacted authors of individual published cases to obtain follow-up data. Data sets were cross-referenced to eliminate duplicate reporting.

Results: We identified 23 children with nephrogenic systemic fibrosis. Seventeen had documented exposure to gadolinium-based contrast agents. Six children had been reported in both the FAERS and the literature, four in the FAERS and the ICNSFR registry and five in all three data sources.

Conclusion: Nephrogenic systemic fibrosis has been rarely reported in children. Although rules related to confidentiality limit the ability to reconcile reports, active pharmaco-vigilance using RADAR (Research on Adverse Drug events And Reports) methodology helped in establishing the number of individual pediatric cases within the three major data sources.

Publication types

  • Meta-Analysis
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adverse Drug Reaction Reporting Systems / statistics & numerical data*
  • Age Distribution
  • Child
  • Female
  • Gadolinium / adverse effects*
  • Humans
  • Incidence
  • Magnetic Resonance Imaging / statistics & numerical data*
  • Male
  • Mandatory Reporting*
  • Nephrogenic Fibrosing Dermopathy / chemically induced*
  • Nephrogenic Fibrosing Dermopathy / epidemiology*
  • Risk Assessment
  • Sex Distribution
  • United States / epidemiology

Substances

  • Gadolinium